Summary of COVID-19 TRV027 studies

1. Robbins et al., The effect of TRV027 on coagulation in COVID‐19: A pilot randomized, placebo‐controlled trial

28 patient TRV027 late treatment RCT: 73% higher mortality (p=1).
Double-blind RCT 30 hospitalized COVID-19 patients in the United Kingdom showing a non-statistically significant trend towards decreased D-dimer levels with TRV027, an angiotensin-(1-7) analogue, compared to placebo. The trial was terminated early due to declining cases.
Dec 2022, British J. Clinical Pharmacology, https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15618, https://c19p.org/robbins

2. Self et al., Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19

290 patient TRV027 late treatment RCT: 52% higher mortality (p=0.25) and 35% worse recovery (p=0.17).
Two RCTs of 510 hospitalized COVID-19 patients showing no significant difference in mortality or days alive without supplemental oxygen with either TRV027 (angiotensin II type 1 receptor-biased ligand) or TXA127 (synthetic angiotensin 1-7) compared to placebo.
Apr 2023, JAMA, https://jamanetwork.com/journals/jama/fullarticle/2803516, https://c19p.org/self5